MAP2K7 and cancer: This readaptation requires higher concentration of MEK inhibitors to achieve therapeutic response, with great limitation to their clinical use due to poor tolerability, and explains the disappointing results in early clinical studies exploring MEK inhibitors in KRAS-mutated cancers [16].